KPMA seeking extension of tax exemption for drug R&D investment.

Published: 2006-05-30 06:59:00

Updated: 2006-05-30 06:59:00

The KPMA is trying hard to keep extension of the government's tax exemption for the drug R&D investment, which was estimated to 530 BW, by quoting other countries where their pharmaceutical industrial development had been largely bolstered by the government's tax privileges for the drug R&D expen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK